Your browser doesn't support javascript.
Combination of thrombolytic and immunosuppressive therapy for coronavirus disease 2019: A case report.
Papamichalis, Panagiotis; Papadogoulas, Antonios; Katsiafylloudis, Periklis; Skoura, Apostolia-Lemonia; Papamichalis, Michail; Neou, Evangelia; Papadopoulos, Dimitrios; Karagiannis, Spyridon; Zafeiridis, Tilemachos; Babalis, Dimitris; Komnos, Apostolos.
  • Papamichalis P; Intensive Care Unit, General Hospital of Larissa, Larissa, Greece. Electronic address: ppapamih@med.uth.gr.
  • Papadogoulas A; Intensive Care Unit, General Hospital of Larissa, Larissa, Greece.
  • Katsiafylloudis P; Intensive Care Unit, General Hospital of Larissa, Larissa, Greece.
  • Skoura AL; Intensive Care Unit, General Hospital of Larissa, Larissa, Greece.
  • Papamichalis M; Cardiology Department, University General Hospital of Larissa, Larissa, Greece.
  • Neou E; Intensive Care Unit, General Hospital of Larissa, Larissa, Greece.
  • Papadopoulos D; Intensive Care Unit, General Hospital of Larissa, Larissa, Greece.
  • Karagiannis S; Intensive Care Unit, General Hospital of Larissa, Larissa, Greece.
  • Zafeiridis T; Intensive Care Unit, General Hospital of Larissa, Larissa, Greece.
  • Babalis D; Emergency Department, General Hospital of Larissa, Larissa, Greece.
  • Komnos A; Intensive Care Unit, General Hospital of Larissa, Larissa, Greece.
Int J Infect Dis ; 97: 90-93, 2020 Aug.
Article in English | MEDLINE | ID: covidwho-457203
ABSTRACT
In a proportion of patients, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a multisystem syndrome characterized by hyperinflammation, acute respiratory distress syndrome (ARDS), and hypercoagulability. A 68-year-old man with coronavirus disease 2019 (COVID-19) was admitted to the intensive care unit with respiratory failure, cytokine release syndrome (CRS), and skin ischemia - microthrombosis. Specific coagulation and inflammatory markers (D-dimer, ferritin, and C-reactive protein), along with the clinical picture, triggered the trial of recombinant tissue plasminogen activator (rt-PA) and tocilizumab. This was followed by resolution of the skin ischemia and CRS, while respiratory parameters improved. No major complications associated with rt-PA or tocilizumab occurred. The combination of rt-PA with targeted anti-inflammatory treatment could be a new therapeutic option for patients with COVID-19, ARDS, hyperinflammation, and increased blood viscosity.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Tissue Plasminogen Activator / Coronavirus Infections / Antibodies, Monoclonal, Humanized / Fibrinolytic Agents / Betacoronavirus / Immunosuppressive Agents Type of study: Case report / Prognostic study / Randomized controlled trials Limits: Aged / Humans / Male Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Tissue Plasminogen Activator / Coronavirus Infections / Antibodies, Monoclonal, Humanized / Fibrinolytic Agents / Betacoronavirus / Immunosuppressive Agents Type of study: Case report / Prognostic study / Randomized controlled trials Limits: Aged / Humans / Male Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2020 Document Type: Article